TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
